



3rd POSTGRADUATE
Lymphoma
Conference

Rome,
March 23-24
2017

VOI Donna Camilla Savelli Hotel

Presidents:

A.M. Carella
P.L. Zinzani

Scientific Committee:

A.M. Carella
B.D. Cheson
S.A. Pileri
A. Younes
P.L. Zinzani

3rd POSTGRADUATE
**Lymphoma
Conference**

Rome,
March 23-24
2017

Faculty

Ranjana	Advani	Stanford, USA
Stephen M.	Ansell	Rochester, USA
Christian	Buske	Ulm, Germany
Angelo Michele	Carella	Genoa, Italy
Jorge J.	Castillo	Boston, USA
Robert	Chen	Duarte, USA
Selina	Chen-Kiang	New York, USA
Bruce D.	Cheson	Washington, USA
Andrew	Davies	Southampton, United Kingdom
Martin	Dreyling	Munich, Germany
John F.	Gerecitano	New York, USA
Olivier	Hermine	Paris, France
Georg	Hess	Mainz, Germany
Wojciech	Jurczak	Kraków, Poland
Steven	Le Gouill	Nantes, France
Brian	Link	Iowa City, USA
Peter	Martin	New York, USA
Ari M.	Melnick	New York, USA
Craig H.	Moskowitz	New York, USA
Owen A.	O'Connor	New York, USA
Stefano A.	Pileri	Milan, Italy
Simon	Rule	Plymouth, United Kingdom
Alexandra	Traverse-Glehen	Lyon, France
Wyndham H.	Wilson	Bethesda, USA
Anas	Younes	New York, USA
Pier Luigi	Zinzani	Bologna, Italy

Thursday, March 23, 2017

8.30 am Welcome and Introduction
A.M. Carella, P.L. Zinzani

Session I

Mantle Cell Lymphoma

Chairmen: M. Dreyling, P. Martin

8.45 am **New research issues**
S. Chen-Kiang

9.00 am General discussion

9.15 am **Front-line treatment in young patients:**
• **European perspective** *M. Dreyling*
• **American perspective** *P. Martin*
• **Role of maintenance therapy** *S. Le Gouill*

10.00 am General discussion

10.15 am **Round Table - Relapsed/refractory setting:**
• **Lenalidomide** *P. Martin*
• **Temsirolimus** *G. Hess*
• **Bortezomib** *O.A. O'Connor*
• **Ibrutinib** *M. Dreyling*
• **Allotransplant** *O. Hermine*

11.30 am General discussion

11.45 am Coffee break

12.00 pm **Newer agents:**
• **Acalabrutinib** *S. Rule*
• **Venetoclax** *S. Le Gouill*
• **Palbociclib** *P. Martin*
• **BGB-3111** *S. Rule*

1.00 pm General discussion

1.15 pm Lunch

Mantle Cell Lymphoma

Mantle Cell Lymphoma

Session II

Hodgkin Lymphoma

Chairman: A. Younes

Relapsed/refractory setting:

2.30 pm **Brentuximab Vedotin**
A. Younes

2.45 pm General discussion

3.00 pm **Nivolumab**
S.M. Ansell

3.15 pm General discussion

3.30 pm **Pembrolizumab**
R. Chen

3.45 pm General discussion

4.00 pm **Response criteria on checkpoint inhibitors treatment**
B.D. Cheson

4.15 pm General discussion

4.30 pm **Autotransplant and beyond**
C.H. Moskowitz

4.45 pm General discussion

5.00 pm **Issues for the Round Table - all speakers:**
• **Treatment choice for CRs during checkpoint inhibitors**
• **Checkpoint inhibitors post allotransplant**
• **Brentuximab Vedotin and checkpoint inhibitors in front-line setting**

5.45 pm General discussion

Hodgkin Lymphoma

Hodgkin Lymphoma

Friday, March 24, 2017

8.00 am LECTURE
News on T-cell lymphoma drugs
R. Advani

8.20 am General discussion

Session III

Follicular Lymphoma

Chairman: B.D. Cheson

8.30 am **WHO news**
S.A. Pileri

8.45 am General discussion

9.00 am **Epigenetic news in follicular lymphoma**
A.M. Melnick

9.15 am General discussion

9.30 am **Transformed follicular lymphoma:
biology and treatment**
B.L. Link

9.45 am General discussion

10.00 am **New biological agents (single agent and combo):**
• **PI3K inhibitors** *A. Younes*
• **BTK inhibitors** *B.D. Cheson*
• **BCL-2 inhibitors** *J. Gerecitano*

10.45 am General discussion

11.00 am **New anti-CD20 monoclonal antibodies**
C. Buske

11.15 am General discussion

11.30 am **Biosimilar rituximab**
W. Jurczak

11.45 am General discussion

12.00 pm Lunch

Follicular Lymphoma

Follicular Lymphoma

Session IV

Diffuse Large B-Cell Lymphoma

Chairman: A.M. Carella

1.00 pm **Debate - Primary mediastinal lymphoma:**
• **R-DA-EPOCH** *W. Wilson*
• **I-II-III generation chemotherapy regimens** *A. Davies*

1.30 pm General discussion

1.45 pm **Double-hit and double-protein-expression lymphomas:
aggressive and refractory lymphomas:**
• **Molecular data** *A. Traverse-Glehen*
• **Clinical presentation** *B.L. Link*

2.15 pm General discussion

2.30 pm **Plasmoblastic lymphoma**
J.J. Castillo

2.45 pm General discussion

3.00 pm **New agents**
S.M. Ansell

3.15 pm General discussion

3.30 pm Arrivederci
A.M. Carella, P.L. Zinzani

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

With an unrestricted educational grant of:



abbvie



SANDOZ A Novartis Division



GENERAL INFORMATION

Meeting Venue

VOI Donna Camilla Savelli Hotel
Via Garibaldi, 27
00153 Rome, Italy
Phone: +39 06 588861
www.hoteldonnacamillasavelli.com

Official Language

English.

Slides

Slides must be in English. Computer videoprojection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible.

Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

Badge

All registered participants and speakers will be given a badge which they must wear to be admitted to the scientific sessions.

Attendance certificate

A certificate will be given to all participants at the end of the meeting.

CME

An application for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-179310
- No. 15,1 CME credits for physicians (disciplines: Hematology, Oncology, Radiotherapy).
- Educational objective: "guidelines-protocols-procedures".

Changes

Parts of the program may be changed without notice.

Organizing Secretariat

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna
Phone: +39 051 4210559 - Fax: +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it